Thymmune Therapeutics is a biotechnology company developing a machine learning-driven thymic cell engineering platform.
Thymmune Therapeutics has raised $37.0M in total funding. The most recent round was Grant. The last funding was announced in September 2023.
Thymmune Therapeutics's investors include Pillar VC, Advanced Research Projects Agency for Health, Arranta Bio, NYBC Ventures, George Church.
Thymmune Therapeutics is headquartered in Cambridge, United States.
Thymmune Therapeutics is a biotechnology company developing a machine learning-driven thymic cell engineering platform.
Thymmune Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Thymmune Therapeutics — Funding & Investors." VCBacked, September 29, 2023, https://www.vcbacked.co/company/thymmune-therapeutics. Accessed August 13, 2026.
VCBacked. (2023). Thymmune Therapeutics — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/thymmune-therapeutics
{{cite web |title=Thymmune Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/thymmune-therapeutics |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated